| Literature DB >> 16771865 |
Flavio Vincenti1, Amado de Andrés, Thomas Becker, Gabriel Choukroun, Edward Cole, José M González-Posada, Mysore A Kumar, Richard Moore, Silvio Nadalin, Björn Nashan, Lionel Rostaing, Kazuhide Saito, Norio Yoshimura.
Abstract
Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16771865 DOI： 10.1111/j.1432-2277.2006.00321.x
Source DB: PubMed Journal: Transpl Int ISSN： 0934-0874 Impact factor: 3.782